Capacity Growth The company expanded a $3.2M manufacturing facility at its San Jose headquarters in 2023, signaling scalable production capabilities and potential for increased instrument and automation demand. This creates opportunities to offer manufacturing equipment, lab automation solutions, system integration services, and ongoing maintenance contracts to support capacity expansion.

High Throughput Demand With the launch and shipments of DNBSEQ T7 and T7 plus platforms, Complete Genomics is increasing high throughput sequencing capability, presenting sales opportunities for sequencing reagents and consumables, library preparation kits, platform maintenance, and professional services to optimize throughput and data quality.

Oncology Focus Attention on oncology through MSK-ACCESS and MSK-IMPACT collaborations powered by SOPHiA DDM signals strong demand for precision medicine tooling, including companion diagnostics, bioinformatics analytics, and integrated data pipelines that connect sequencing data to clinical insights.

Strategic Ownership The acquisition by Swiss Rockets AG points to an evolving enterprise strategy with potential for multi year commitments and portfolio diversification. This creates a pathway for enterprise wide solutions, procurement partnerships, and cross selling across business units.

Ecosystem Potential Complete Genomics offers end to end capabilities from sample extraction to data analysis, including lab automation and DNBSEQ sequencing, enabling bundled offerings and cross selling into research institutions focused on genomics powered by AI driven analytics and cloud based data management.